- Home
- ESLA vs STTK Comparison
ESLA vs STTK Comparison
Compare ESLA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- STTK
- Stock Information
- Founded
- ESLA 2021
- STTK 2016
- Country
- ESLA United States
- STTK United States
- Employees
- ESLA N/A
- STTK N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- STTK Health Care
- Exchange
- ESLA Nasdaq
- STTK Nasdaq
- Market Cap
- ESLA 35.5M
- STTK 37.6M
- IPO Year
- ESLA N/A
- STTK 2020
- Fundamental
- Price
- ESLA $0.94
- STTK $1.00
- Analyst Decision
- ESLA Strong Buy
- STTK Hold
- Analyst Count
- ESLA 1
- STTK 4
- Target Price
- ESLA $16.00
- STTK $3.00
- AVG Volume (30 Days)
- ESLA 521.4K
- STTK 112.0K
- Earning Date
- ESLA 08-20-2025
- STTK 07-31-2025
- Dividend Yield
- ESLA N/A
- STTK N/A
- EPS Growth
- ESLA N/A
- STTK N/A
- EPS
- ESLA N/A
- STTK N/A
- Revenue
- ESLA N/A
- STTK $4,606,000.00
- Revenue This Year
- ESLA $101.09
- STTK N/A
- Revenue Next Year
- ESLA N/A
- STTK N/A
- P/E Ratio
- ESLA N/A
- STTK N/A
- Revenue Growth
- ESLA N/A
- STTK 69.65
- 52 Week Low
- ESLA $0.63
- STTK $0.69
- 52 Week High
- ESLA $3.23
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- ESLA 46.99
- STTK 47.54
- Support Level
- ESLA $0.89
- STTK $0.91
- Resistance Level
- ESLA $1.02
- STTK $1.14
- Average True Range (ATR)
- ESLA 0.09
- STTK 0.08
- MACD
- ESLA -0.00
- STTK -0.01
- Stochastic Oscillator
- ESLA 21.16
- STTK 28.35
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.